Lucid Diagnostics Achieves Publication Milestone for EsoGuard Testing
Lucid Diagnostics Inc. (Nasdaq: LUCD), a leader in cancer prevention medical diagnostics, recently celebrated the acceptance of its manuscript detailing the ESOGUARD BE-1 prospective multicenter clinical validation study. This groundbreaking study showcases the unparalleled performance of the EsoGuard® Esophageal DNA Test in effectively screening high-risk patients for esophageal precancer. The news marks another significant step for Lucid in the ongoing battle against esophageal cancer.
Strengthening the Case for Medicare Coverage
The publication of the ESOGUARD BE-1 study reinforces Lucid’s clinical evidence package as it formally seeks Medicare coverage for the EsoGuard test. Lucid's Chairman and Chief Executive Officer, Lishan Aklog, M.D., expressed gratitude to the dedicated team of investigators. Aklog stated, "This fourth clinical validation study accepted for peer-reviewed publication enables us to approach the MolDX program with comprehensive data. This data is crucial for our mission to pursue Medicare coverage effectively.
Impact on Esophageal Cancer Prevention
The data presented in the manuscript follows an extensive review of multiple studies. It shows high sensitivity and negative predictive value for detecting Barrett's Esophagus, a known precursor to esophageal cancer. Within high-risk populations undergoing non-endoscopic EsoGuard testing, the study revealed that sensitivity and negative predictive value reached approximately 88% and 99% respectively. This performance underlines the reliability of EsoGuard as an effective screening tool.
Publication in a Prestigious Journal
Now published in The American Journal of Gastroenterology, the ESOGUARD BE-1 study is the latest among several clinical validation efforts conducted by Lucid Diagnostics. Prior studies also demonstrated the strong effectiveness of the EsoGuard test, establishing a robust body of evidence supporting its clinical use.
Leading Biological Research
Serving as the lead author for the manuscript is Nicholas J. Shaheen, M.D., M.P.H., a prominent figure in the field of esophageal precancer research. His leadership, alongside contributions from renowned academic institutions, showcases a collaborative effort in advancing cancer detection methodologies.
About Lucid Diagnostics
Lucid Diagnostics Inc. is dedicated to transforming cancer prevention through innovative medical diagnostics. The company's flagship product, the EsoGuard® Esophageal DNA Test, is designed specifically for patients at high risk of developing esophageal precancer and cancer, particularly those suffering from gastroesophageal reflux disease (GERD).
Innovative Screening Solutions
Lucid aims to enhance early detection of esophageal precancer by utilizing non-invasive procedures and offering tools like the EsoCheck® Esophageal Cell Collection Device. These innovations are critical in improving health outcomes for patients who are often overlooked in routine screenings.
Frequently Asked Questions
What is the focus of the ESOGUARD BE-1 study?
The ESOGUARD BE-1 study evaluates the effectiveness of the EsoGuard® Esophageal DNA Test for detecting esophageal precancer in high-risk patients.
What significance does the publication hold for Lucid Diagnostics?
It represents a critical step in Lucid's efforts to receive Medicare coverage for its EsoGuard test, which could enhance access for at-risk populations.
Who were the key contributors to the study?
The study had significant input from Nicholas J. Shaheen, M.D., as well as numerous collaborators from leading academic medical centers.
What are the primary performance metrics of the EsoGuard test?
The sensitivity and negative predictive value of the EsoGuard test are approximately 88% and 99%, demonstrating its reliability in clinical practice.
How can I learn more about Lucid Diagnostics?
For detailed information on Lucid and its array of diagnostic solutions, visit their official website at www.luciddx.com.
